吉妥珠单抗奥唑米星在急性髓系白血病中的应用
CD33在几乎所有急性髓系白血病(AML)患者的白血病原始细胞上表达,吉妥珠单抗奥唑米星(GO;Mylotarg)是一种靶向CD33的抗体药物偶联物。GO在急性早幼粒细胞白血病中最有效,但也能诱导其他类型AML缓解,于2000年在美国获得加速批准;因一项大型随访研究显示无生存改善且早期死亡增加,制造商于2010年自愿撤回美国新药申请。近期一项Meta分析报告,在有利和中等风险细胞遗传学成人AML中,强化诱导化疗联合GO组生存优于未联合GO组,但不良风险AML中未观察到该获益,监管机构正重新评估GO。
要点
- GO在急性早幼粒细胞白血病中最有效,也可诱导其他类型AML缓解。
- Meta分析显示有利和中等风险细胞遗传学成人AML中,强化诱导化疗联合GO组生存优于未联合GO组,不良风险组无此获益。
- rs12459419 CC基因型患者可能从GO治疗中获益,但需确认。
核心结论
- GO在急性早幼粒细胞白血病中最有效,但也能诱导其他类型AML缓解;Meta分析显示有利和中等风险细胞遗传学成人AML中,强化诱导化疗联合GO组生存优于未联合GO组,不良风险组无此获益,GO正被监管机构重新评估。
研究设计与样本
- 综述,聚焦靶向CD33的抗体药物偶联物GO在AML中的治疗应用。
主要发现
- GO于2000年在美国获得加速批准,但因一项大型随访研究显示无生存改善且早期死亡增加,制造商于2010年自愿撤回美国新药申请。
- Meta分析报告,有利和中等风险细胞遗传学成人AML中,强化诱导化疗联合GO组生存优于未联合GO组,不良风险AML中未观察到该获益。
- 对GO的应答多样,需要预测性生物学应答标志物;ATP结合盒转运蛋白活性及AML原始细胞上CD33表达可能预测应答,但缺乏已建立的临床检测和前瞻性验证。
- CD33单核苷酸多态性可能具有预测性,尤其是rs12459419,其次要T等位基因导致全长CD33表达降低并优先翻译不被GO识别的剪接变异体。
- 回顾性分析数据提示仅rs12459419 CC基因型患者可能从GO治疗中获益,但需确认。
关键数值与推荐
- AML细胞对卡奇霉素的敏感性差异超过100000倍,但尚无可用检测方法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏已建立的临床检测和前瞻性验证。
- rs12459419 CC基因型患者可能获益的回顾性分析数据需确认。
- AML细胞对卡奇霉素敏感性差异超过100000倍,但有用检测方法不可用。
- 新型CD33靶向药物能否在GO获益患者中更有效和/或改善GO未获益患者结局,以及其安全使用所需的支持治疗要求,目前尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in some. Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate delivering a DNA-damaging calicheamicin derivative. GO is most effective in acute promyelocytic leukemia but induces remissions in other AML types and received accelerated approval in the US in 2000. However, because a large follow-up study showed no survival improvement and increased early deaths the drug manufacturer voluntarily withdrew the US New Drug Application in 2010. More recently, a meta-analysis of data from several trials reported better survival in adults with favorable- and intermediate-risk cytogenetics but not adverse-risk AML randomized to receive GO along with intensive induction chemotherapy. As a result, GO is being re-evaluated by regulatory agencies. Responses to GO are diverse and predictive biological response markers are needed. Besides cytogenetic risk, ATP-binding cassette transporter activity and possibly CD33 display on AML blasts may predict response, but established clinical assays and prospective validation are lacking. Single-nucleotide polymorphisms in CD33 may also be predictive, most notably rs12459419 where the minor T-allele leads to decreased display of full-length CD33 and preferential translation of a splice variant not recognized by GO. Data from retrospective analyses suggest only patients with the rs12459419 CC genotype may benefit from GO therapy but confirmation is needed. Most important may be markers for AML cell sensitivity to calicheamicin, which varies over 100 000-fold, but useful assays are unavailable. Novel CD33-targeted drugs may overcome some of GO's limitations but it is currently unknown whether such drugs will be more effective in patients benefitting from GO and/or improve outcomes in patients not benefitting from GO, and what the supportive care requirements will be to enable their safe use.
引用
- Godwin CD, Gale RP, Walter RB, et al. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017. PMID: 28607471. doi:10.1038/leu.2017.187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。